High IDO‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma

Nivolumab belongs to the standard therapy in the second‐line setting of metastatic renal cell carcinoma (mRCC). Although deep and long‐lasting responses are seen in some patients, the majority of patients will further progress. PD‐L1 is still under critical evaluation as a predictive biomarker. Thus...

Descripción completa

Detalles Bibliográficos
Autores principales: Seeber, Andreas, Klinglmair, Gerald, Fritz, Josef, Steinkohl, Fabian, Zimmer, Kai‐Christian, Aigner, Friedrich, Horninger, Wolfgang, Gastl, Günther, Zelger, Bettina, Brunner, Andrea, Pichler, Renate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980224/
https://www.ncbi.nlm.nih.gov/pubmed/29498788
http://dx.doi.org/10.1111/cas.13560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980224/
https://www.ncbi.nlm.nih.gov/pubmed/29498788
http://dx.doi.org/10.1111/cas.13560

Ejemplares similares